221 related articles for article (PubMed ID: 17497898)
1. Role of carbonate in the cytotoxicity of carboplatin.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2007 Jun; 20(6):896-904. PubMed ID: 17497898
[TBL] [Abstract][Full Text] [Related]
2. Activation of carboplatin by carbonate.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2006 Jan; 19(1):139-49. PubMed ID: 16411667
[TBL] [Abstract][Full Text] [Related]
3. Formation of carbonato and hydroxo complexes in the reaction of platinum anticancer drugs with carbonate.
Di Pasqua AJ; Centerwall CR; Kerwood DJ; Dabrowiak JC
Inorg Chem; 2009 Feb; 48(3):1192-7. PubMed ID: 19113934
[TBL] [Abstract][Full Text] [Related]
4. Modification and uptake of a cisplatin carbonato complex by Jurkat cells.
Centerwall CR; Tacka KA; Kerwood DJ; Goodisman J; Toms BB; Dubowy RL; Dabrowiak JC
Mol Pharmacol; 2006 Jul; 70(1):348-55. PubMed ID: 16632646
[TBL] [Abstract][Full Text] [Related]
5. Adsorption of the Pt(II) anticancer drug carboplatin by mesoporous silica.
Di Pasqua AJ; Wallner S; Kerwood DJ; Dabrowiak JC
Chem Biodivers; 2009 Sep; 6(9):1343-9. PubMed ID: 19774597
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
Liu W; Chen X; Xie M; Lou L; Ye Q; Yu Y; Hou S
J Inorg Biochem; 2008 Oct; 102(10):1942-6. PubMed ID: 18707762
[TBL] [Abstract][Full Text] [Related]
7. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
8. Modification of carboplatin by Jurkat cells.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dabrowiak JC
J Inorg Biochem; 2007 Oct; 101(10):1438-41. PubMed ID: 17655933
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
10. New extracellular resistance mechanism for cisplatin.
Centerwall CR; Kerwood DJ; Goodisman J; Toms BB; Dabrowiak JC
J Inorg Biochem; 2008; 102(5-6):1044-9. PubMed ID: 18294693
[TBL] [Abstract][Full Text] [Related]
11. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
12. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin carbonato complexes. Implications for uptake, antitumor properties, and toxicity.
Centerwall CR; Goodisman J; Kerwood DJ; Dabrowiak JC
J Am Chem Soc; 2005 Sep; 127(37):12768-9. PubMed ID: 16159248
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.
Kröning R; Katz D; Lichtenstein AK; Nagami GT
Br J Cancer; 1999 Jan; 79(2):293-9. PubMed ID: 9888471
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
Hah SS; Stivers KM; de Vere White RW; Henderson PT
Chem Res Toxicol; 2006 May; 19(5):622-6. PubMed ID: 16696564
[TBL] [Abstract][Full Text] [Related]
17. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells.
Tacka KA; Szalda D; Souid AK; Goodisman J; Dabrowiak JC
Chem Res Toxicol; 2004 Nov; 17(11):1434-44. PubMed ID: 15540941
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
19. Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.
Cubo L; Quiroga AG; Zhang J; Thomas DS; Carnero A; Navarro-Ranninger C; Berners-Price SJ
Dalton Trans; 2009 May; (18):3457-66. PubMed ID: 19381408
[TBL] [Abstract][Full Text] [Related]
20. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
Almotairy ARZ; Gandin V; Morrison L; Marzano C; Montagner D; Erxleben A
J Inorg Biochem; 2017 Dec; 177():1-7. PubMed ID: 28918353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
